ABCG2 and chronic myelogenous leukemia, BCR-ABL1 positive: Polymorphisms in ABC transporters responsible for active drug efflux may have a role in predicting response to TKIs, even if the exact mechanism of MDR-ABC transporter-mediated resistance in CML is unclear (20).